Navigation Links
Takeda's investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
Date:10/6/2008

Combined results from two Phase 3 studies presented at the American College of Gastroenterology Annual Scientific Meeting (ACG) in Orlando, Fla., demonstrated that TAK-390MR resulted in higher healing rates than lansoprazole among patients with more severe grades of erosive esophagitis (EE). TAK-390MR combines dexlansoprazole with a Dual Delayed Release (DDR) formulation, designed to provide two separate releases of drug for extended duration of acid suppression.

"These data are encouraging, as they suggest that TAK-390MR may provide an innovative new treatment option for patients with GERD, including those with more severe grades of erosive esophagitis," said David Peura, M.D., professor of medicine, University of Virginia Health System.

As part of the Phase 3 clinical trials, 4,092 patients were assessed for overall EE healing at week eight in two identically designed trials. Patients were randomized to receive 60 mg or 90 mg of TAK-390MR or 30 mg of lansoprazole. A retrospective, integrated analysis showed the difference in healing rates, or therapeutic gains, between 60 mg and 90 mg of TAK-390MR and 30 mg of lansoprazole, increased as the severity of EE increased. Therapeutic gains were greatest in patients with the most severe grade of EE (grade D): 12 percent for 60 mg (n=74) and 20 percent for 90 mg (n=83) of TAK-390MR. There were no significant differences in adverse events observed between the treatment groups.

"The development of TAK-390MR is another example of Takeda's commitment to patients who suffer from GERD and erosive esophagitis," said Dr. Stuart Atkinson, vice president of clinical science at Takeda. "TAK-390MR has the potential to serve as an important new treatment option for physicians and patients. If approved, it would be the first PPI that employs a dual delayed release formulation, delivering medication in two separate releases."

Additional TAK-390MR data being presented at ACG includes:


'/>"/>
Contact: Geoff Curtis
gcurtis@wcpglobal.com
312-550-8138
WeissComm Partners
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage
2. NEW DATA FOR PAZOPANIB - GSKS LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS
3. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
4. UAB study shows investigational drug may treat biliary cancers
5. Investigational anti-restenosis drug pimecrolimus disappoints
6. Investigational drug tested for preventing muscle fiber death in muscular dystrophy
7. Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
8. New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets
9. UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam
10. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
11. MetaCure(TM) Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Ticket Down is a reputable source for ... friendly exhibition match at the Red Bull Arena in ... that was left standing as the best team in the ... largest football competition and even embarrassed the host nation Brazilian ... Germany was led by seven players that called Bayern Munich ...
(Date:7/30/2014)... Church, VA (PRWEB) July 30, 2014 ... , Understanding Advanced Critical Thinking Skills and Innovative ... **Presented by Immel Resources and FDAnews**, Sept. 17-18, ... CAPA has been the #1 reason for 483 ... makes it clear: Developing a successful CAPA program ...
(Date:7/30/2014)... education in sub-Saharan Africa is being revitalized and ... increasing enrollment, broadening curricula, upgrading Internet access and ... , In the first substantial publication by participants ... (MEPI), more than 225 authors detailed progress being ... in a supplement being published today by the ...
(Date:7/30/2014)... to artemisinin, the main drug to treat malaria, ... Plasmodium falciparum ( P. falciparum ) ... caused by a genetic mutation in the parasites. ... opposed to a standard three-day coursehas proved highly ... findings published today in the New England ...
(Date:7/30/2014)... Steven Reinberg HealthDay Reporter ... year in the United States, at least 2,000 Americans die ... said Wednesday. Heat waves, heat stroke or sun stroke ... between 2006 and 2010, according to the U.S. Centers for ... a severe loss of body heat -- accounted for 63 ...
Breaking Medicine News(10 mins):Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 2Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 4Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 3
... therapy where a radioactive source is placed in or just ... to be cancerous. The traditional// external beam radiation therapy ... the tumor, outside the body of a person. ... left in place either temporarily or permanently. For this purpose ...
... James Reilly, former president of the Irish Medical Organization (IMO) ... Election for Fine Gael// . Previously, Nora Owen, the party’s ... contestant is seeking the nomination in the Dublin North constituency ... selection convention, to be held on the 2nd of May. ...
... reliability of implanted cardiac pacemakers and defibrillators having improved ... malfunction// at times. ,For the thousands of ... reliability of these devices is an important issue. The ... whereas the defibrillator delivers a shock to restart a ...
... during older age results in grave consequences. People who ... through diet and exercise. This increases their physical function// ... lead to a loss of functional independence in the ... Dennis T. Villareal from Washington University School of Medicine ...
... Bolivar University in Caracas found that Lactobacillus casei (L ... flatulence capacity// and increased the nutritional value. Beans are ... the developing countries. ,Marisela Granito led the ... beans but not compromising on the nutritional value. The ...
... 60 and younger have an increased susceptibility to depression ... of the study are especially significant when considering// health-care ... patients who don't become depressed. The results of the ... of the Archives of Internal Medicine. ,According ...
Cached Medicine News:Health News:Brachytherapy Shows Promise for Cancer Treatment 2Health News:Reliability of Pacemakers and Defibrillators to be Improved 2Health News:Depression Accompanies Heart Attacks in Younger Women 2
(Date:7/30/2014)...  Hospira, Inc. (NYSE: HSP ), ... infusion technologies, today reported results for the second ... the quarter were $1.1 billion and adjusted* diluted ... specified items as described later in this press ... Generally Accepted Accounting Principles (GAAP) basis, second-quarter 2014 ...
(Date:7/30/2014)... SAN ANTONIO , July 30, 2014 /PRNewswire/ ... technology company focused on innovating lifesaving devices and ... closed $4.5 million in Series A financing, which ... .  Proceeds from the deal will allow Bluegrass ... Inside-Out Access Catheter System, enhance manufacturing capabilities, and ...
(Date:7/30/2014)... , July 30, 2014  PDL BioPharma, Inc. (PDL) ... management will participate in the Jefferies 2014 Boston Healthcare ... Massachusetts. The conference will occur on August 6, 2014 and ... Inc. PDL BioPharma manages a portfolio of ... et al. antibody humanization patents and license agreements with ...
Breaking Medicine Technology:Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30Hospira Reports Second-Quarter 2014 Results 31Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2
... Dec. 14 Cardinal Health today announced that executives of the ... Goldman Sachs CEO Unplugged Conference on Jan. 6 at Noon ... 28th Annual J.P. Morgan Healthcare Conference on Jan. 12 ... Francisco. , At these events, company executives will discuss Cardinal ...
... , STAMFORD, Conn., Dec. 14 Zargis ... SPDE ) and a spin-off from Siemens Corporate Research (NYSE: ... selling its award-winning Zargis Cardioscan(TM) system on Amazon.com, America,s largest ... were jointly named Popular Science magazine,s ...
Cached Medicine Technology:Cardinal Health Executives to Speak at Two Investor Events in January 2Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com 2
Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...
The pediatric blanket provides full coverage for pediatric patient care. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also red...
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The design of the large pediatric underbody blanket conveniently warms the large child or small adult patient while allowing full access for surgeons and staff....
Medicine Products: